Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity

J.A. Landheer; M.S. de Bruin-Weller; C. Boonacker; D.J. Hijnen; C.A.F.M. Bruijnzeel - Koomen; H. Rockmann

doi:10.1016/j.jaad.2014.07.031

Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity

J.A. Landheer
, M.S. de Bruin-Weller
, C. Boonacker
, D.J. Hijnen
, C.A.F.M. Bruijnzeel - Koomen
, H. Rockmann

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Serum thymus and activation-regulated chemokine (sTARC) levels reflect disease severity of atopic dermatitis (AD) in small study populations. It remains unclear whether sTARC is a reliable outcome measurement for AD severity in heterogeneous AD populations in daily practice.

OBJECTIVE: We sought to assess the utility of sTARC as a biomarker for monitoring AD severity in adults in daily practice.

METHODS: sTARC, clinical skin score (Six Area, Six Sign AD [SASSAD]), and body surface area measurements were collected from all adult patients with AD visiting our clinic between March 2009 and March 2012, at first visit or exacerbation (baseline). In addition, data from short-term and long-term follow-up visits were collected.

RESULTS: At baseline sTARC levels ranged widely (n = 320; minimum-maximum: 3-50,400 pg/mL) and sTARC and SASSAD or body surface area correlated moderately. In the majority of patients, sTARC and SASSAD or body surface area changed congruently during follow-up.

LIMITATIONS: Data were collected retrospectively.

CONCLUSION: sTARC may represent a suitable biomarker for monitoring of AD severity in daily practice.

Original language	English
Pages (from-to)	1160-1166
Number of pages	7
Journal	Journal of the American Academy of Dermatology
Volume	71
Issue number	6
DOIs	https://doi.org/10.1016/j.jaad.2014.07.031
Publication status	Published - Dec 2014

Keywords

Adult
Biomarkers
Body Surface Area
Chemokine CCL17
Dermatitis, Atopic
Female
Follow-Up Studies
Humans
Male
Middle Aged
Retrospective Studies
Severity of Illness Index
Young Adult

Access to Document

10.1016/j.jaad.2014.07.031

Cite this

@article{f115b8f4e247423f81ebd3667b8ac450,

title = "Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity",

abstract = "BACKGROUND: Serum thymus and activation-regulated chemokine (sTARC) levels reflect disease severity of atopic dermatitis (AD) in small study populations. It remains unclear whether sTARC is a reliable outcome measurement for AD severity in heterogeneous AD populations in daily practice.OBJECTIVE: We sought to assess the utility of sTARC as a biomarker for monitoring AD severity in adults in daily practice.METHODS: sTARC, clinical skin score (Six Area, Six Sign AD [SASSAD]), and body surface area measurements were collected from all adult patients with AD visiting our clinic between March 2009 and March 2012, at first visit or exacerbation (baseline). In addition, data from short-term and long-term follow-up visits were collected.RESULTS: At baseline sTARC levels ranged widely (n = 320; minimum-maximum: 3-50,400 pg/mL) and sTARC and SASSAD or body surface area correlated moderately. In the majority of patients, sTARC and SASSAD or body surface area changed congruently during follow-up.LIMITATIONS: Data were collected retrospectively.CONCLUSION: sTARC may represent a suitable biomarker for monitoring of AD severity in daily practice.",

keywords = "Adult, Biomarkers, Body Surface Area, Chemokine CCL17, Dermatitis, Atopic, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Young Adult",

author = "J.A. Landheer and \{de Bruin-Weller\}, M.S. and C. Boonacker and D.J. Hijnen and \{Bruijnzeel - Koomen\}, C.A.F.M. and H. Rockmann",

year = "2014",

month = dec,

doi = "10.1016/j.jaad.2014.07.031",

language = "English",

volume = "71",

pages = "1160--1166",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity

AU - Landheer, J.A.

AU - de Bruin-Weller, M.S.

AU - Boonacker, C.

AU - Hijnen, D.J.

AU - Bruijnzeel - Koomen, C.A.F.M.

AU - Rockmann, H.

PY - 2014/12

Y1 - 2014/12

N2 - BACKGROUND: Serum thymus and activation-regulated chemokine (sTARC) levels reflect disease severity of atopic dermatitis (AD) in small study populations. It remains unclear whether sTARC is a reliable outcome measurement for AD severity in heterogeneous AD populations in daily practice.OBJECTIVE: We sought to assess the utility of sTARC as a biomarker for monitoring AD severity in adults in daily practice.METHODS: sTARC, clinical skin score (Six Area, Six Sign AD [SASSAD]), and body surface area measurements were collected from all adult patients with AD visiting our clinic between March 2009 and March 2012, at first visit or exacerbation (baseline). In addition, data from short-term and long-term follow-up visits were collected.RESULTS: At baseline sTARC levels ranged widely (n = 320; minimum-maximum: 3-50,400 pg/mL) and sTARC and SASSAD or body surface area correlated moderately. In the majority of patients, sTARC and SASSAD or body surface area changed congruently during follow-up.LIMITATIONS: Data were collected retrospectively.CONCLUSION: sTARC may represent a suitable biomarker for monitoring of AD severity in daily practice.

AB - BACKGROUND: Serum thymus and activation-regulated chemokine (sTARC) levels reflect disease severity of atopic dermatitis (AD) in small study populations. It remains unclear whether sTARC is a reliable outcome measurement for AD severity in heterogeneous AD populations in daily practice.OBJECTIVE: We sought to assess the utility of sTARC as a biomarker for monitoring AD severity in adults in daily practice.METHODS: sTARC, clinical skin score (Six Area, Six Sign AD [SASSAD]), and body surface area measurements were collected from all adult patients with AD visiting our clinic between March 2009 and March 2012, at first visit or exacerbation (baseline). In addition, data from short-term and long-term follow-up visits were collected.RESULTS: At baseline sTARC levels ranged widely (n = 320; minimum-maximum: 3-50,400 pg/mL) and sTARC and SASSAD or body surface area correlated moderately. In the majority of patients, sTARC and SASSAD or body surface area changed congruently during follow-up.LIMITATIONS: Data were collected retrospectively.CONCLUSION: sTARC may represent a suitable biomarker for monitoring of AD severity in daily practice.

KW - Adult

KW - Biomarkers

KW - Body Surface Area

KW - Chemokine CCL17

KW - Dermatitis, Atopic

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Severity of Illness Index

KW - Young Adult

U2 - 10.1016/j.jaad.2014.07.031

DO - 10.1016/j.jaad.2014.07.031

M3 - Article

C2 - 25199679

SN - 0190-9622

VL - 71

SP - 1160

EP - 1166

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 6

ER -

Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity

Abstract

Keywords

Access to Document

Fingerprint

Cite this